Related Experiment Videos
Encapsulating peritoneal sclerosis.
1Tsuchiya General Hospital, Hiroshima, Japan. h_kawanishi@tsuchiya-hp.jp
Nephrology (Carlton, Vic.)
|June 17, 2005
Summary
Encapsulating peritoneal sclerosis (EPS), once fatal, is now treatable in peritoneal dialysis (PD) patients. Early recognition of gastrointestinal symptoms and timely steroid treatment are crucial for managing this PD complication.
Area of Science:
- Nephrology
- Gastroenterology
Background:
- Encapsulating peritoneal sclerosis (EPS) has historically been viewed as a fatal complication of peritoneal dialysis (PD).
- EPS incidence in PD patients ranges from 0.7% to 7.3%, increasing with long-term PD treatment duration.
- Long-term PD (over 8 years) with conventional solutions significantly elevates EPS risk.
Purpose of the Study:
- To re-evaluate the prognosis and treatment strategies for encapsulating peritoneal sclerosis (EPS) in peritoneal dialysis (PD) patients.
- To emphasize the importance of considering EPS in PD patients presenting with gastrointestinal symptoms.
Main Methods:
- Review of historical data and clinical observations regarding EPS in PD patients.
- Analysis of treatment outcomes based on disease stage, including steroid therapy and surgical interventions.
Main Results:
- EPS is not invariably fatal and can be effectively managed with appropriate treatment.
- Steroid therapy is a primary treatment modality for EPS.
- Surgical intervention (laparotomy and enterolysis) may be necessary for persistent bowel obstruction.
Conclusions:
- Encapsulating peritoneal sclerosis (EPS) is a manageable complication of peritoneal dialysis (PD), not a fatal outcome.
- Prompt diagnosis and staged treatment, including steroids and potentially surgery, are key to successful EPS management.
- Vigilant monitoring of long-term PD patients, especially those with gastrointestinal symptoms, is essential for early EPS detection.